Bicara Therapeutics Inc. (NASDAQ:BCAX) will release earnings for its fourth quarter before the opening bell on Monday, March 30.

Analysts expect the Boston, Massachusetts-based company to report a quarterly loss of 65 cents per share, versus a loss of 39 cents per share in the year-ago period, according to Benzinga Pro.

On March 4, Bicara Therapeutics announced inducement grant under Nasdaq Listing Rule 5635(c)(4).

Bicara Therapeutics shares fell 1.6% to trade at $18.62 on Friday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • B of A Securities analyst Tazeen Ahmad initiated coverage on the stock with a Buy rating and a price target of $35 on March 25, 2026. This analyst has an accuracy rate of 57%.
  • Wedbush analyst David Nierengarten maintained an Outperform rating with a price target of $30 on Jan. 13, 2026. This analyst has an accuracy rate of 70%.
  • BTIG analyst Jeet Mukherjee initiated coverage on the stock with a Buy rating and a price target of $28 on Jan. 8, 2026. This analyst has an accuracy rate of 51%.
  • Mizuho analyst Joseph Cantanzaro initiated coverage on the stock with a Neutral rating and a price target of $18 on Dec. 18, 2025. This analyst has an accuracy rate of 59%.
  • Wells Fargo analyst Eva Fortea Verdejo maintained an Equal-Weight rating and raised the price target from $8 to $11 on Nov. 11, 2025. This analyst has an accuracy rate of 66%.

Considering buying BCAX stock? Here’s what analysts think:

Photo via Shutterstock